THRB and neoplasm: Despite the limited sampling depth of this targeted scRNAseq platform when compared with our high-throughput, DNA-based TRB repertoire analyses of the same samples, an average of 45.5% (range, 27.4 – 65.3% across six tumors) of the TRA/TRB-CDR3 sequence pairs identified in tumor-infiltrating T cells were observed in two or more cells, representing “expanded” clones (Figure 3B).